14 results about "Enterobacteriaceae" patented technology

Provided is a method for detecting the presence or absence and / or amount of Enterobacteriaceae bacteria in a food or drink sample, an environmental sample, or a biological sample, in a short period of time, easily and efficiently. The method includes a step of simultaneously detecting the presence or absence and / or amount of at least two or more different genera of Enterobacteriaceae bacteria in a sample based on an antigen-antibody reaction.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and / or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and / or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

The present invention relates to a brown rice fermentation product and its uses, more specifically, to the use of the brown rice fermentation product to moisten the intestines, improve bowel movements, and contribute to the regulation of the intestinal microbiota. The present invention has found that the brown rice fermentation product can improve constipation, have NO removal effects, and down-regulate the relative expression levels of the nos1, nos2a, and nos2b genes. Treatment with the brown rice fermentation product can regulate the species richness of the intestinal microbiota of constipated zebrafish, with certain effects on species uniformity and diversity, increasing the abundance of beneficial bacteria (Bacteroidetes) and decreasing the abundance of harmful bacteria (Firmicutes, Aeromonas, Enterobacteriaceae). The brown rice fermentation product of the present invention can be widely used in the food industry as a functional ingredient.

The invention belongs to the technical field of natural composition preparation, and particularly relates to earthworm polypeptide oral liquid and a preparation method thereof. According to the invention, 15-20 parts of earthworm peptide powder and 5-8 parts of conch peptide powder are specifically combined, and the earthworm peptide powder in the composition is beneficial to promoting the utilization of sugar by muscles, so that the glycemic index is reduced; the conch peptide powder can regulate starvation hormone, reduce the proportion of pathogenic bacteria in intestinal tracts and improve the abundance of beneficial bacteria. Therefore, when the polypeptide composition is used for preparing the earthworm polypeptide oral liquid for resisting sugar and inhibiting harmful intestinal flora, the anti-sugar effect can be achieved, meanwhile, the increase of the number of enterobacter and / or enterococcus in the intestinal tract is effectively inhibited, and the occurrence of intestinal inflammation is reduced. Therefore, according to the technical scheme, the application range of the earthworms is enriched, and the application value of the market is widened.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

The invention relates to application of cacumen biotae alcohol for reversing drug resistance of polymyxin. The application is realized through the function of the platycladol for inhibiting the MCR-1 enzyme, specifically, the combination of the platycladol and the polymyxin B can recover the bactericidal effect of the polymyxin B on the MCR-1 positive enterobacter, and the bactericidal effect is a synergistic effect. According to the combined medication scheme, host cells can be protected in a cell infection model, the death rate can be remarkably reduced in a mouse peritonitis infection model, and no obvious toxicity is observed in the treatment dosage of platycladi alcohol. The invention provides a therapeutic scheme for solving the problem of drug resistance of clinical polymyxin B mediated by MCR-1.

The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

The invention discloses a plant source extract for inhibiting multi-drug-resistant bacteria and application of the plant source extract in intestinal flora balance, relates to the technical field of biological medicine and micro-ecological regulation and control, and in particular relates to a plant source extract for inhibiting multi-drug-resistant bacteria and application of the plant source extract in intestinal flora balance. The active ingredient of the composition is prepared by compounding a rhizome aqueous extract of a plant A, a peel alcohol extract of a plant B and a leaf supercritical fluid extract of a plant C according to a specific weight ratio. The preparation method comprises the following steps: respectively preparing the extracts, and physically mixing the extracts into a uniform mixture under dark and low-temperature conditions. The composition can effectively inhibit multi-drug-resistant pathogenic bacteria (such as antibiotic-resistant enterobacteriaceae bacteria) in intestinal tracts of individuals and promote growth of effective microbial communities (such as short-chain fatty acid producing bacteria). The invention further provides an oral intestinal microecology regulator containing the composition, the dosage form of the oral intestinal microecology regulator can be enteric capsules, microencapsulated particles or powder, and the oral intestinal microecology regulator has the positive effect of regulating intestinal microecology.

This invention discloses a method for preparing a strain of Lactobacillus saccharidus and its application in the preservation of chilled fresh meat, including the following steps: Step (1) Initial screening: Take 1.0 g of environmental sample, add 9 mL of sterile physiological saline, shake at 37℃ and 200 r / min for 30 min, sonicate for 10 min, then serially dilute to 10⁻⁴-10⁻⁶, take 100 μL and spread it on MRS solid medium, incubate at 37℃ for 48 h, pick single colonies and purify 3 times; Step (2) Antibacterial screening: Use 8 strains of putrefactive bacteria such as Enterobacter and Escherichia coli as indicator bacteria. The preparation method of this Lactobacillus saccharidus strain is based on natural sources, ensuring high safety and making it a suitable alternative to chemical preservatives. It exhibits significant inhibitory effects on major spoilage bacteria (such as Pseudomonas and Enterobacteriaceae) and pathogenic bacteria in chilled meat. Its low-temperature resistance (4℃) and acid and alkali resistance make it suitable for the storage environment of chilled meat. After application, it can reduce the total bacterial count, TVB-N content, pH value, and drip loss rate, delay color changes, and effectively extend the shelf life of chilled meat.

The invention discloses a nucleic acid-protein binding method, an amide induced expression system and application thereof. The nucleic acid sequence is a manipulation sequence, and the protein is DNA binding protein (regulatory protein). The amide induced expression system comprises a promoter, a manipulation sequence, a regulatory protein and an inducing substance. In a strain that expresses one or more regulatory proteins, gene expression is performed using a promoter sequence that may contain an amide-inducing manipulation sequence, such as a substance comprising a "CO-NH2" amide group, comprising but not limited to urea (carbamide), formamide, acetamide, propanamide, methacrylamide, acrylamide and other short-chain amide substances as inducers, and can achieve an inducible expression effect in strains of nocardiaceae, bacillus, corynebacterium, enterobacteriaceae, pseudomonas and the like.

The present application relates to the field of microbial technology, and particularly relates to the application of butyric acid-producing Enterobacter as an anti-Eimeria tenella probiotic. In the present application, the E. tenella infection model induced by an antibiotic cocktail is used to explore the effect of butyric acid-producing Enterobacter DSM 26588 on the development of E. tenella. The butyric acid-producing Enterobacter DSM 26588 inhibits the expression of the EtGFAT gene of the gamete of E. tenella, thereby inhibiting the development of the gamete; improves the intestinal lesions caused by E. tenella infection, reduces the pathological damage to the intestine, and reduces the output of E. tenella oocysts, with an ACI value of 162, and has good anti-coccidial effect.